- Gilead Sciences
Gilead Sciences, a biopharma company, achieves bold ambitions to help make the world a healthier place, leading in HIV, liver disease, cancer inflammation
- Gilead Sciences: Company
Learn about the biopharmaceutical company Gilead Sciences, including mission, vision, values, history, impact, leadership, therapeutic areas and other information
- Medicines - Gilead Sciences
Access the list of approved Gilead therapies across virology including HIV, liver disease including hepatitis and primary biliary cholangitis, oncology inflammation
- Newsroom | Gilead
This is our global website, intended for visitors seeking information on Gilead’s worldwide business Some content on this site is not intended for people outside the United States Visit our Global Operations page for links to our international corporate websites
- Yeztugo Lenacapavir Is Now the First and Only FDA Approved HIV . . .
The FDA approval of Gilead’s New Drug Applications (NDAs) for Yeztugo was supported by data from the Phase 3 PURPOSE 1 and PURPOSE 2 trials conducted by Gilead
- Gilead Sciences, Inc. - Investor Relations
At Gilead, we’re committed to creating a healthier world for everyone – no matter the challenges ahead of us For more than 30 years, we’ve pursued the impossible, chased it down, tackled it for answers and surrounded it for a way in
- Virology, Inflammation, Oncology Pipeline | Gilead
Through science and innovative partnerships, Gilead expands research and development programs in virology, oncology, inflammation Learn about our pipeline
- Gilead Sciences
Más de 18 000 empleados de Gilead en todo el mundo trabajan para hacer avanzar la innovación científica, ayudar a garantizar que nuestros medicamentos lleguen a quienes los necesitan y marcar la diferencia en las comunidades en las que vivimos y trabajamos
|